Book Information

Book ID Asin: 099840750X
Book Title: The Pharmagellan Guide to Biotech Forecasting and Valuation
Book Author: Frank S. David MD PhD,Seth Robey PhD,Andrew Matthews MD,Robert Simison,Tracy Cutchlow,Denise Clifton,David Sable MD
Book Format and Price:
Book Format Name: Kindle
Book Format Price: $68.65
Book Format Name: Paperback
Book Format Price: $72.74
Book Price: $72.74
Book Category: Books, Business & Money, Finance and unknown
Book Rating: 45 ratings

Book Product Detail

• Best Sellers Rank: #204,364 in Books (See Top 100 in Books)
  • #54 in Pharmaceutical & Biotechnology Industry (Books)
  • #65 in Valuation (Books)
  • #85 in Biotechnology (Books)

• Customer Reviews:
  4.2 out of 5 stars 45 ratings

Book Review

Name: Smartypants
Rating: 5.0 out of 5 stars
Title: Probably the most useful biotech forecasting tool aside from my HP12c
Date: Reviewed in the United States on February 2, 2017
Review: Finally. A practical guide to valuation in biotech. If you're looking to figure out whether you should use IRR or NPV or how to build that NPV spreadsheet, this is not the book for you. You don't have to be an expert number cruncher but the book assumes a basic financial knowledge and understanding of general valuation concepts. This is why the book is so useful. Models are only as good as what goes into them. David, who clearly has deep industry experience, does a fantastic job of framing a process for thinking through key assumptions including revenue size and growth and development and commercialization costs. Equally useful are commonly used benchmarks for these assumptions (of course only to be used in absence of any other knowledge). The book is to be used "just in time" and doesn't require you read it beginning to end.

Name: GK
Rating: 3.0 out of 5 stars
Title: Overpriced and concise
Date: Reviewed in the United States on August 31, 2020
Review: Book is ~100 pages with some chapter being literally 2 pages long. Essentially the book provides a quick guide to forecasting and provides references on what numbers make good assumptions for these models. I would say the book should be valued between $30-50

Name: Charles
Rating: 5.0 out of 5 stars
Title: Concise and extraordinarily useful
Date: Reviewed in the United States on August 15, 2018
Review: Sure, it's not cheap for a book of only 100 pages. But the information contained in the Pharmagellan Guide is straight to-the-point. There isn't any fluff (I can't say the same for some 1,000+ page textbooks). I strongly recommend this book to anyone involved in biotech or pharma valuation.

One particularly useful component: the citations and Pharmagellan's analyses. For example, Pharmagellan did a study of clinical trial success times, which you can incorporate into your valuation models.

Name: RV Chand
Rating: 5.0 out of 5 stars
Title: Short Yet Impactful
Date: Reviewed in the United States on April 1, 2018
Review: The book might seem shorter than expected for the steep price. However, this is because all the fluff is culled away. Each section is direct and useful as a reference. This guide contained many facts and figures useful for valuation and modelling which should create value for readers.

Name: Magali
Rating: 5.0 out of 5 stars
Title: I couldn't be any happier about this book
Date: Reviewed in the United States on June 10, 2018
Review: As a 26yr-old beginner in this journey, I couldn't be any happier about this book. For those of us who come from the finance sector but still love & plan to work in Biotech, it's impossible not to find it hard to make an accurate analysis of so many pre-commercial biotech COs.
Frank's book is THE guide you will need from now on to make either a comprehensive analysis or an investment decision. Its insightful, its very well-written and it gives you all the tools you'll use

Name: Dan Sparklingeyes
Rating: 5.0 out of 5 stars
Title: A must-read for any biotech investor!
Date: Reviewed in the United States on October 27, 2019
Review: A must-read for anyone involved in biotech. As an investor, I found myself updating my financial models after every chapter of the book. The author takes a data-driven approach to answering difficult-to-answer questions in biotech forecasting. The book helped me see value in companies where I didn’t think it existed before and vice versa.

Name: Doug Martin
Rating: 5.0 out of 5 stars
Title: Thoroughly researched and well organized
Date: Reviewed in the United States on January 14, 2017
Review: Read book cover to cover the day I received it. The book is organized very well and provides an excellent structure and guide for those new to the field as well as interesting benchmarks and data for the more experienced and seasoned.

I highly recommend for buy and sell-side analysts seeking to refine their own valuations or understand others, consultants who conduct pipeline commercial assessments or conduct diligence/ support licensing & partnerships, and those in in-line business/corporate development and their internal customers in senior management and on the Board.

I am impressed by how the authors managed to concisely review materials in a way that is useful to the aforementioned varied stakeholders and experience sets. I plan to keep it nearby as relevant issues surface and to purchase for others to help ensure a structured approach built on the valuation principles and data outlined.

Name: J. Rock
Rating: 5.0 out of 5 stars
Title: Five Stars
Date: Reviewed in the United States on September 3, 2017
Review: Clear and concise, an enduring helpful tool.

Home | Contact  | DMCA